Skip to main content
Premium Trial:

Request an Annual Quote

Melanoma MDx Firm DermTech Withdraws Planned $15M IPO

NEW YORK (GenomeWeb) – Melanoma test development firm DermTech is pulling its proposed initial public offering.

The La Jolla, Calif.-based firm filed a request with the US Securities and Exchange Commission on Thursday saying it seeks an "immediate withdrawal" of its Form S-1 "as it has determined not to proceed with an offering at this time." It did not provide a reason for the withdrawal.

DermTech filed its registration form in May to offer its shares on the Nasdaq Capital Market under ticker symbol "DMTK." The Maxim Group and Feltl & Co., were the underwriters on the offering. It originally planned an offering of up to $25 million of its shares but lowered its target to $15 million in August.

The firm develops gene expression tests for diagnosing skin conditions, including skin cancer, inflammatory diseases, and age-related conditions. Its technology uses an "adhesive patch biopsy" that provides a tissue sample non-invasively, DermTech said in its Form S-1. Skin cells are then analyzed via a qPCR-based method.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.